NASDAQ:NXGL NEXGEL Q3 2023 Earnings Report $2.80 -0.03 (-1.20%) As of 04/17/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings History NEXGEL EPS ResultsActual EPS-$0.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANEXGEL Revenue ResultsActual Revenue$1.22 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANEXGEL Announcement DetailsQuarterQ3 2023Date11/13/2023TimeN/AConference Call DateMonday, November 13, 2023Conference Call Time4:30PM ETUpcoming EarningsNEXGEL's Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by NEXGEL Q3 2023 Earnings Call TranscriptProvided by QuartrNovember 13, 2023 ShareLink copied to clipboard.There are 6 speakers on the call. Operator00:00:00Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to Nextel's Third Quarter 2023 Earnings Conference Call. I will now turn the call over to Walter Pinto, Managing Director of KCSA Strategic Communications for introductions. Please go ahead. Speaker 100:00:19Thank you, operator. Good afternoon and welcome everyone to the Nextel Third Quarter 2023 Earnings Conference Call. I'm joined today by Adam Levy, Chief Executive Officer Adam Drafzic, Chief Financial Officer of NextGel. Before we begin, I'd like to remind everyone that statements made during today's conference call may be deemed forward looking statements within the meaning of the Safe Harbor of the Private Securities Litigation Reform Act of 1995, and actual results may differ materially due to a variety of risks, uncertainties and other factors. For a detailed discussion of some of the ongoing risks and uncertainties in the company's business, I refer you to the press release issued this evening and filed with the SEC on Form 8 ks as well as the company's reports filed periodically with the SEC. Speaker 100:01:03The company disclaims any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by law. With that, it's my pleasure to turn the call over to Mr. Adam Levy. Adam, please go ahead. Speaker 200:01:20Thank you, Walter. Thank you everyone for joining us today to discuss our Q3 2023 financial and operating results. We are pleased to deliver yet another record revenue quarter in Q3 of $1,220,000 an increase of 115 percent year over year and up slightly as compared to revenue of $1,170,000 for the Q2 of 2023. Of note, the $2,300,000 in revenue generated the last two quarters exceeds our full year of 2022 revenue. Growth year over year was driven by an increase in contract manufacturing. Speaker 200:01:56This is our 2nd consecutive quarter of revenue contribution from the acquisition of a 50% interest in the JV with CG Labs. The return on this $500,000 investment into the JV, which we recently made the last payment on, has proved to be an excellent mutually beneficial transaction and one in which we have quickly realized the benefits. It has contributed materially to our top line growth and is accretive to the bottom line as well. We also have yet to realize the full benefits to margins as that will come as the new equipment is installed and validated. We expect the first equipment to come online in Q1 of 2024. Speaker 200:02:35We recently announced executing the supply agreement with AbbVie to be the supplier of gel pads for their rapid acoustic pulse device. In December of 2021, AbbVie acquired the owner of this technology, Soliton, for $550,000,000 in cash after its RASONIC device demonstrated significant improvement in the appearance of cellulite. After extensive due diligence from AbbVie for many months, our hydrogels were chosen as the required razor to its razor blade model for each procedure to be done. Our ability to meet the high standards of AbbVie demonstrates the uniqueness of our technology and the fact that a company of their size would select us is something we are very proud of. We expect the RASONIC device to be launched next year. Speaker 200:03:21We have been making necessary preparations to ensure we are fully prepared for this potentially significant and impactful revenue opportunity for Nextel. Our branded consumer products grew year over year 54% and quarter over quarter by 37%. This was led by Silverseal, which continues to be a hero product for us, consistently gaining popularity and positive reviews. This product is a unique hydrogel dressing for wounds and burns. The sterile silver patches are FDA cleared and have been clinically shown to kill 99% of staph, MRSA and strep. Speaker 200:03:57They've also been shown to reduce scarring and pain in wounds. Silverseal was a behind the counter hospital device for many years and our messaging of hospital grade product now available for home use has resonated with our consumers. In North America, we are making good progress with Enigma Health for retail distribution. Now that we have fully vetted the audience for our leading products and have gained steady traction in the market, it is time to put these products on shelves. Our active discussions with many leading retailers have been going well and we realistically could see our products on shelves by this coming summer. Speaker 200:04:33Last quarter, we provided an update on our amblyopia patch. We have since launched the product and have shipped to approximately 30 ophthalmology offices and the feedback thus far has been very positive. We are currently monitoring reorder rates, adoption and consumer feedback to plan the next phase of our rollout strategy. Importantly, we have also made significant strides improving our gross profit, going from a gross loss in Q1 to a gross profit in Q2 and improving again in Q3. Gross margins improved sequentially to 28.1 percent in Q3 compared to 15% in the prior quarter. Speaker 200:05:14Our net loss in the 3rd quarter also continued to trend lower quarter over quarter in line with our goal to become profitable in 2024 from $814,000 in Q1 to $695,000 in Q2 to $552,000 in Q3. Included in our net loss of $552,000 for the 3rd quarter are approximately $95,000 of non cash items. Our cash and cash equivalents decreased from $4,300,000 at June 30, 2023 to $3,300,000 at September 30, 2023. The delta between our improved net loss during the quarter and the net cash decrease over the period was related to an increase in accounts receivables and property, plant and equipment investments. As we mentioned last quarter, the customers of CG Converting and Packaging require lengthier payment terms. Speaker 200:06:08Their payment terms are closer to 90 days as compared to Nextel's core business customers who typically receive 30 day payment terms. Therefore, AR increased during the period by $208,000 We also invested $361,000 in additional property, plant and equipment during the quarter. Before I turn the call over to Adam, while Q3 was a significant quarter for us, we also have a lot to be excited about as we head into next year. Given our growth into retail and new markets and our branded product line, as well as the opportunity to onboard new customers, we have strategically invested in inventory and equipment to increase capacity and automation to meet the significant increase in demand we expect for our proprietary hydrogels in 2024 and beyond. We expect our revenue to continue to grow year over year, margin expansion and the net loss decrease to continue as we move towards profitability, which is always our highest priority. Speaker 200:07:06With that, I would like to turn the call over to our CFO, Adam Draupsek. Adam? Speaker 300:07:11Thank you, Adam. Today, I'll review financial highlights of our Q3 2023 results. For the Q3 of 2023, revenue totaled $1,220,000 an increase of $653,000 or 115 percent as compared to $568,000 for the same period the year prior. The quarterly increase in overall revenues was primarily due to sales growth in contract manufacturing and branded products year over year, including revenue contribution from the joint venture formed with CG Labs. Gross profit for the Q3 of 2023 was $344,000 compared to a gross profit of $148,000 for the same prior year period. Speaker 300:08:04Gross profit margin for the Q3 of 2023 was 28.2% compared to 26.1% for the same period the year before. Gross margin increased sequentially to 28.2% during the Q3 of 2023 as compared to 15% during the Q2 of 2023. Total operating expenses, including R and D and SG and A expenses, decreased to $956,000 for the 3 months ended September 30, 2023, compared to $1,190,000 for the prior year period. The year over year decrease was attributable to a decrease in total SG and A and R and D expenses period over period. Net loss for the quarter ended September 30, 2023 improved to $552,000 or $0.10 per basic and diluted share compared to net loss of $1,200,000 or $0.22 per basic and diluted share for the same period in 2022. Speaker 300:09:13Net loss also improved sequentially to $552,000 during the Q3 of 2023 as compared to $695,000 during the Q2 of 2023. As of September 30, 2023, Next Shell had approximately $3,300,000 of cash. During the quarter, the company invested in capital expenditures for new equipment and increased its capacity at Texas facility to prepare us to execute our new supply agreements in 2024. As of November 13, 2023, Nextel had 5,000,717,629 shares of common stock outstanding. I would now like to open the call for questions. Speaker 300:10:00Operator? Operator00:10:04Thank you. We will now be conducting a question and answer session. Our first question comes from Nav Rahman with Maxim Group. Please proceed with your question. Speaker 400:10:38Hi, everyone. Congratulations on the progress and thanks for taking our questions. I have a few, if I could start. On the supply agreement with AbbVie for the Risonic product, could you talk a little more about the market opportunity and the potential economics to NextGen in 2024? Speaker 200:10:57Sure. Hey, Nas, good to hear from you again. So look, we're under NDA with AbbVie. So I can't obviously share their forecast. We're obviously not in control of their launch. Speaker 200:11:08But I can say that you really couldn't ask for a much better partner in a product like this. And I can say that if they are successful, this is extremely significant and impactful revenue for us. Speaker 400:11:24Got it. And on kind of a similar note, you also signed a deal with Halion earlier this year for a product launch by them. Do you have any updates on the product or do you have any potential timelines on when we could hear more about the product itself and a potential launch? Speaker 200:11:40Yes, that product is actually a little bit further off than the AbbVie product. So think about that for or certainly an update somewhere in mid-twenty 24 as they're probably targeting the end of 2024 has always been kind of our guidance on that product. Speaker 400:11:57Got it. That's helpful. So on those two points, now more of like a high level strategic question I've had and had conversations about is obviously had a very, very transformative 2023 and you have a lot of different initiatives going on. Based on internal thinking and with everything that's happened, what do you think it's like the most significant or potential strategic growth driver at Speaker 200:12:19least in 2024? Unquestionably, it's probably AbbVie. There's going to be some other good things, but that one is staring us right in the face. Speaker 400:12:32Got it. Do you have any thoughts on how much of that revenue that could as we could compromise? Speaker 200:12:39Again, look, this is it will be very significant, we think. They paid more than $500,000,000 $550,000,000 for this product. I can't imagine they're going to go out. And again, I don't have any direct knowledge and I'm under NDA, but I can't imagine we're going to go out weak with that kind of investment. So if they really do the job that we think they can do on that product, that is by far the biggest opportunity we have. Speaker 400:13:04Understood. On the Pridemores, you commented a little about the amblyopia patch launch. Could you provide more color on what feedback you got from physicians regarding the patch? And I was also curious, in terms of the actual use of the patch, have you found that they're being mainly given to, I guess, new patients or switches? And do you have any idea of how many patients are either newer switches like in terms of percentages? Speaker 200:13:34So, great question. So, as far as so far the feedback has been terrific. Generally, they're being given to existing patients because the patients with the worst irritation and the worst issues are the ones that we're using a different patch. The children are complaining. They've got those red rings around their eyes that are either blistering or very irritated. Speaker 200:13:54So those are who I think the doctors are giving it to 1st and foremost. And then they're going to offer it to other people. And as the practice goes through, patients come in every month to get a different set in. They seem to be now steadily reordering and steadily giving it to more and more patients. I think what we need to understand and don't have the full picture of yet is exactly what percentage of their patients are going to switch to this, right? Speaker 200:14:17It's a slight premium or a significant premium. Actually, it's about 50% more expensive than something else you can buy on Amazon. And I think what we need to determine is, is everybody just going to like it because it feels so much better or are really the patients that are going to use it the ones with the worst eye irritations and the worst problems. And that, of course, defines the size of the market. So we're getting a lot of feedback from these doctors. Speaker 200:14:40We're doing a lot of research. We're talking to some of the patients. They want to tell us some great stories. And as we determine what our next step should be, that will kind of tell us where we should put our resources and how we should really try to ramp this thing. Speaker 400:14:53That was helpful. Thanks. And also on that point on AMLIAOPIA, have you gotten any inquiries for potentially very large wholesale orders beyond the initial orders or Speaker 200:15:07reorders? So, no, I mean, we've gotten some large practice orders, practices that have ordered 100 boxes at a time, but those are still small in the overall scheme of things until you get a lot of practices. I don't think we're quite ready yet and that's part of what we're trying to determine before we engage one of those more expensive like professional sales forces that might go out to a whole bunch of doctors' offices. We want to understand the product, understand the pitch, understand what we're doing because that's not cheap to engage someone like that. But when we're ready, that is definitely one of the things that we will talk about and make a plan around. Speaker 400:15:42Understood. So obviously, you have a lot of initiatives ongoing and very meeting near term initiatives. But I also also want to talk a little about your pipeline. Could you provide a potential update on the progress and development of the 510 devices you're working on? Speaker 200:15:57Sure. So the main thing that we had for the 510 devices that pushed them off was our inability to at scale and at a effective manufacturing cost to produce them with the dies and pumps that we currently had. We have tested the new prototype dies. They worked very, very well and we're now going ahead and ordering those dies to come in. And so we're probably going to be ready to manufacture product in the next 60 to 90 days and then we will submit it for testing and start moving those products forward again. Speaker 200:16:28Fortunately for us, despite that delay, we've had so much to work on that that's only one project out of several. But we do think it's an important project and we are going to pick it back up as soon as we can manufacture it effectively. Speaker 400:16:42That was very helpful. Thanks for taking my questions and I'll get back in queue. Speaker 100:16:48Okay. Thank you. Operator00:16:58Our next question comes from Chris Vachowsky. Please proceed with your question. Speaker 500:17:06Good afternoon. Congratulations on very good results. Speaker 200:17:09Thank you, Chris. Speaker 500:17:12So during the LD Micro conference, you said that you wouldn't need any additional cash to reach profitability next year, given this quarter's cash yields. Are you do you still confirm this statement? Speaker 200:17:30Yes. So we are not going to need any cash to reach profitability. But I've also always said that if an opportunity presented itself or there was something accretive that we could purchase, that we would at that point do a financing tied directly to that. So as of right now, our cash loss was well below $500,000 and we still have $3,300,000 Fortunately, when you're ramping with some of these bigger companies that we now have, you're not dealing with payment terms like when you go into retail. So I think we're going to be okay right now. Speaker 200:18:02We're projecting profitability before we run out of cash with a pretty good cushion. But if there is something that we need to do and it means that that's going to allow us to scale and not have a hiccup in the way we scale, at that point we'll think about adding some cash. But as of right now, unless there's a really good reason that we're going to announce at the same time, we don't need any cash. Speaker 500:18:23Okay. This is very good to hear. So congratulations on great growth in Silverseal. And if I heard you correctly, Silverseal had very good sequential growth as well as annual. And was there any part of your business that shrunk sequentially because sequentially revenue did not grow that much? Speaker 200:18:49Sequentially revenues did not grow that much, but Silverseal grew. You always have a couple of products that you get rid of that didn't work out. So when you're launching a new product, especially when we test our products on Amazon, which is our model, those products will have a very high advertising rate compared to the profitability. So they're really not profitable as you start acquiring various customers. And then what we do is we watch the overall advertising drop if the product is popular because you get reorders, you get subscribed and saves and then you have to get to a certain threshold, which is probably around 25% to 30% tacos and our heroes are much lower than that. Speaker 200:19:28But then the product seem to be scaling. We every all the time, not every product we put out works, we're dropping products that don't meet that criteria. So yes, there's a few products that we drop, that's part of the weeding and calling process. But the real growth in Silverseal is no longer going to come from sequential growth on Amazon because that's a limited market. The next step for us is going to be retail and foreign markets and that's what's coming in the near future. Speaker 500:19:56Okay. And the retail, you said, is going to be sometime next year? Speaker 200:20:02Yes. I think it's reasonable to think midsummer around that time. There's just a process that retailers go through. All of our meetings have gone extremely well. There's a lot of interest on several products, not just SilverSeal, because we have probably 3 to 4 hero products now that we think would be viable at retail. Speaker 200:20:18And as I get a clearer picture, we'll give you updates on the next quarterly call as to exactly when we think we'll have products in the marketplace. Speaker 500:20:26Okay. And it seems that at least financially, it seems that you fit the profile of a company undergoing strong sequential growth, your accounts receivable are growing, you're investing more money in inventory. So any comments for Q4? Are we going to see sequential growth again? Speaker 200:20:48We really don't give guidance as to the quarters. I will tell you that you're going to continue to see very strong growth from us. But remember, we also have very large customers that tend to kick in periodically. So it doesn't look like a straight line up like a flat hill. It looks more like a staircase. Speaker 200:21:04So it is always possible that you have a flat quarter. We kind of had a flat quarter this quarter. But then as new things are announced and new customers come online, you'll see large jumps. And that's kind of the pattern I think you can kind of take as a general description going forward. Does that make sense? Speaker 500:21:20Yes, yes. Thanks. Okay, this is it for me. Good luck to us all. Speaker 200:21:24Thank you very Operator00:21:29much. We have reached the end of our question and answer session. This concludes today's teleconference. Thank you for your participation. You may disconnect your lines now.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallNEXGEL Q3 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) NEXGEL Earnings HeadlinesNEXGEL CEO Adam Levy to Present at Planet MicroCap Showcase 2025April 9, 2025 | msn.comNEXGEL to Present at the Planet MicroCap Showcase in Las Vegas, NV April 22nd-24thApril 7, 2025 | markets.businessinsider.comTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public. April 19, 2025 | Paradigm Press (Ad)NEXGEL Reports Record-Breaking 2024 Financial PerformanceMarch 27, 2025 | msn.comNEXGEL, Inc. (NASDAQ:NXGL) Q4 2024 Earnings Call TranscriptMarch 26, 2025 | insidermonkey.comEarnings call transcript: Nexgel Q4 2024 sees revenue surge, stock jumpsMarch 26, 2025 | investing.comSee More NEXGEL Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NEXGEL? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NEXGEL and other key companies, straight to your email. Email Address About NEXGELNEXGEL (NASDAQ:NXGL) manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.View NEXGEL ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 6 speakers on the call. Operator00:00:00Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to Nextel's Third Quarter 2023 Earnings Conference Call. I will now turn the call over to Walter Pinto, Managing Director of KCSA Strategic Communications for introductions. Please go ahead. Speaker 100:00:19Thank you, operator. Good afternoon and welcome everyone to the Nextel Third Quarter 2023 Earnings Conference Call. I'm joined today by Adam Levy, Chief Executive Officer Adam Drafzic, Chief Financial Officer of NextGel. Before we begin, I'd like to remind everyone that statements made during today's conference call may be deemed forward looking statements within the meaning of the Safe Harbor of the Private Securities Litigation Reform Act of 1995, and actual results may differ materially due to a variety of risks, uncertainties and other factors. For a detailed discussion of some of the ongoing risks and uncertainties in the company's business, I refer you to the press release issued this evening and filed with the SEC on Form 8 ks as well as the company's reports filed periodically with the SEC. Speaker 100:01:03The company disclaims any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by law. With that, it's my pleasure to turn the call over to Mr. Adam Levy. Adam, please go ahead. Speaker 200:01:20Thank you, Walter. Thank you everyone for joining us today to discuss our Q3 2023 financial and operating results. We are pleased to deliver yet another record revenue quarter in Q3 of $1,220,000 an increase of 115 percent year over year and up slightly as compared to revenue of $1,170,000 for the Q2 of 2023. Of note, the $2,300,000 in revenue generated the last two quarters exceeds our full year of 2022 revenue. Growth year over year was driven by an increase in contract manufacturing. Speaker 200:01:56This is our 2nd consecutive quarter of revenue contribution from the acquisition of a 50% interest in the JV with CG Labs. The return on this $500,000 investment into the JV, which we recently made the last payment on, has proved to be an excellent mutually beneficial transaction and one in which we have quickly realized the benefits. It has contributed materially to our top line growth and is accretive to the bottom line as well. We also have yet to realize the full benefits to margins as that will come as the new equipment is installed and validated. We expect the first equipment to come online in Q1 of 2024. Speaker 200:02:35We recently announced executing the supply agreement with AbbVie to be the supplier of gel pads for their rapid acoustic pulse device. In December of 2021, AbbVie acquired the owner of this technology, Soliton, for $550,000,000 in cash after its RASONIC device demonstrated significant improvement in the appearance of cellulite. After extensive due diligence from AbbVie for many months, our hydrogels were chosen as the required razor to its razor blade model for each procedure to be done. Our ability to meet the high standards of AbbVie demonstrates the uniqueness of our technology and the fact that a company of their size would select us is something we are very proud of. We expect the RASONIC device to be launched next year. Speaker 200:03:21We have been making necessary preparations to ensure we are fully prepared for this potentially significant and impactful revenue opportunity for Nextel. Our branded consumer products grew year over year 54% and quarter over quarter by 37%. This was led by Silverseal, which continues to be a hero product for us, consistently gaining popularity and positive reviews. This product is a unique hydrogel dressing for wounds and burns. The sterile silver patches are FDA cleared and have been clinically shown to kill 99% of staph, MRSA and strep. Speaker 200:03:57They've also been shown to reduce scarring and pain in wounds. Silverseal was a behind the counter hospital device for many years and our messaging of hospital grade product now available for home use has resonated with our consumers. In North America, we are making good progress with Enigma Health for retail distribution. Now that we have fully vetted the audience for our leading products and have gained steady traction in the market, it is time to put these products on shelves. Our active discussions with many leading retailers have been going well and we realistically could see our products on shelves by this coming summer. Speaker 200:04:33Last quarter, we provided an update on our amblyopia patch. We have since launched the product and have shipped to approximately 30 ophthalmology offices and the feedback thus far has been very positive. We are currently monitoring reorder rates, adoption and consumer feedback to plan the next phase of our rollout strategy. Importantly, we have also made significant strides improving our gross profit, going from a gross loss in Q1 to a gross profit in Q2 and improving again in Q3. Gross margins improved sequentially to 28.1 percent in Q3 compared to 15% in the prior quarter. Speaker 200:05:14Our net loss in the 3rd quarter also continued to trend lower quarter over quarter in line with our goal to become profitable in 2024 from $814,000 in Q1 to $695,000 in Q2 to $552,000 in Q3. Included in our net loss of $552,000 for the 3rd quarter are approximately $95,000 of non cash items. Our cash and cash equivalents decreased from $4,300,000 at June 30, 2023 to $3,300,000 at September 30, 2023. The delta between our improved net loss during the quarter and the net cash decrease over the period was related to an increase in accounts receivables and property, plant and equipment investments. As we mentioned last quarter, the customers of CG Converting and Packaging require lengthier payment terms. Speaker 200:06:08Their payment terms are closer to 90 days as compared to Nextel's core business customers who typically receive 30 day payment terms. Therefore, AR increased during the period by $208,000 We also invested $361,000 in additional property, plant and equipment during the quarter. Before I turn the call over to Adam, while Q3 was a significant quarter for us, we also have a lot to be excited about as we head into next year. Given our growth into retail and new markets and our branded product line, as well as the opportunity to onboard new customers, we have strategically invested in inventory and equipment to increase capacity and automation to meet the significant increase in demand we expect for our proprietary hydrogels in 2024 and beyond. We expect our revenue to continue to grow year over year, margin expansion and the net loss decrease to continue as we move towards profitability, which is always our highest priority. Speaker 200:07:06With that, I would like to turn the call over to our CFO, Adam Draupsek. Adam? Speaker 300:07:11Thank you, Adam. Today, I'll review financial highlights of our Q3 2023 results. For the Q3 of 2023, revenue totaled $1,220,000 an increase of $653,000 or 115 percent as compared to $568,000 for the same period the year prior. The quarterly increase in overall revenues was primarily due to sales growth in contract manufacturing and branded products year over year, including revenue contribution from the joint venture formed with CG Labs. Gross profit for the Q3 of 2023 was $344,000 compared to a gross profit of $148,000 for the same prior year period. Speaker 300:08:04Gross profit margin for the Q3 of 2023 was 28.2% compared to 26.1% for the same period the year before. Gross margin increased sequentially to 28.2% during the Q3 of 2023 as compared to 15% during the Q2 of 2023. Total operating expenses, including R and D and SG and A expenses, decreased to $956,000 for the 3 months ended September 30, 2023, compared to $1,190,000 for the prior year period. The year over year decrease was attributable to a decrease in total SG and A and R and D expenses period over period. Net loss for the quarter ended September 30, 2023 improved to $552,000 or $0.10 per basic and diluted share compared to net loss of $1,200,000 or $0.22 per basic and diluted share for the same period in 2022. Speaker 300:09:13Net loss also improved sequentially to $552,000 during the Q3 of 2023 as compared to $695,000 during the Q2 of 2023. As of September 30, 2023, Next Shell had approximately $3,300,000 of cash. During the quarter, the company invested in capital expenditures for new equipment and increased its capacity at Texas facility to prepare us to execute our new supply agreements in 2024. As of November 13, 2023, Nextel had 5,000,717,629 shares of common stock outstanding. I would now like to open the call for questions. Speaker 300:10:00Operator? Operator00:10:04Thank you. We will now be conducting a question and answer session. Our first question comes from Nav Rahman with Maxim Group. Please proceed with your question. Speaker 400:10:38Hi, everyone. Congratulations on the progress and thanks for taking our questions. I have a few, if I could start. On the supply agreement with AbbVie for the Risonic product, could you talk a little more about the market opportunity and the potential economics to NextGen in 2024? Speaker 200:10:57Sure. Hey, Nas, good to hear from you again. So look, we're under NDA with AbbVie. So I can't obviously share their forecast. We're obviously not in control of their launch. Speaker 200:11:08But I can say that you really couldn't ask for a much better partner in a product like this. And I can say that if they are successful, this is extremely significant and impactful revenue for us. Speaker 400:11:24Got it. And on kind of a similar note, you also signed a deal with Halion earlier this year for a product launch by them. Do you have any updates on the product or do you have any potential timelines on when we could hear more about the product itself and a potential launch? Speaker 200:11:40Yes, that product is actually a little bit further off than the AbbVie product. So think about that for or certainly an update somewhere in mid-twenty 24 as they're probably targeting the end of 2024 has always been kind of our guidance on that product. Speaker 400:11:57Got it. That's helpful. So on those two points, now more of like a high level strategic question I've had and had conversations about is obviously had a very, very transformative 2023 and you have a lot of different initiatives going on. Based on internal thinking and with everything that's happened, what do you think it's like the most significant or potential strategic growth driver at Speaker 200:12:19least in 2024? Unquestionably, it's probably AbbVie. There's going to be some other good things, but that one is staring us right in the face. Speaker 400:12:32Got it. Do you have any thoughts on how much of that revenue that could as we could compromise? Speaker 200:12:39Again, look, this is it will be very significant, we think. They paid more than $500,000,000 $550,000,000 for this product. I can't imagine they're going to go out. And again, I don't have any direct knowledge and I'm under NDA, but I can't imagine we're going to go out weak with that kind of investment. So if they really do the job that we think they can do on that product, that is by far the biggest opportunity we have. Speaker 400:13:04Understood. On the Pridemores, you commented a little about the amblyopia patch launch. Could you provide more color on what feedback you got from physicians regarding the patch? And I was also curious, in terms of the actual use of the patch, have you found that they're being mainly given to, I guess, new patients or switches? And do you have any idea of how many patients are either newer switches like in terms of percentages? Speaker 200:13:34So, great question. So, as far as so far the feedback has been terrific. Generally, they're being given to existing patients because the patients with the worst irritation and the worst issues are the ones that we're using a different patch. The children are complaining. They've got those red rings around their eyes that are either blistering or very irritated. Speaker 200:13:54So those are who I think the doctors are giving it to 1st and foremost. And then they're going to offer it to other people. And as the practice goes through, patients come in every month to get a different set in. They seem to be now steadily reordering and steadily giving it to more and more patients. I think what we need to understand and don't have the full picture of yet is exactly what percentage of their patients are going to switch to this, right? Speaker 200:14:17It's a slight premium or a significant premium. Actually, it's about 50% more expensive than something else you can buy on Amazon. And I think what we need to determine is, is everybody just going to like it because it feels so much better or are really the patients that are going to use it the ones with the worst eye irritations and the worst problems. And that, of course, defines the size of the market. So we're getting a lot of feedback from these doctors. Speaker 200:14:40We're doing a lot of research. We're talking to some of the patients. They want to tell us some great stories. And as we determine what our next step should be, that will kind of tell us where we should put our resources and how we should really try to ramp this thing. Speaker 400:14:53That was helpful. Thanks. And also on that point on AMLIAOPIA, have you gotten any inquiries for potentially very large wholesale orders beyond the initial orders or Speaker 200:15:07reorders? So, no, I mean, we've gotten some large practice orders, practices that have ordered 100 boxes at a time, but those are still small in the overall scheme of things until you get a lot of practices. I don't think we're quite ready yet and that's part of what we're trying to determine before we engage one of those more expensive like professional sales forces that might go out to a whole bunch of doctors' offices. We want to understand the product, understand the pitch, understand what we're doing because that's not cheap to engage someone like that. But when we're ready, that is definitely one of the things that we will talk about and make a plan around. Speaker 400:15:42Understood. So obviously, you have a lot of initiatives ongoing and very meeting near term initiatives. But I also also want to talk a little about your pipeline. Could you provide a potential update on the progress and development of the 510 devices you're working on? Speaker 200:15:57Sure. So the main thing that we had for the 510 devices that pushed them off was our inability to at scale and at a effective manufacturing cost to produce them with the dies and pumps that we currently had. We have tested the new prototype dies. They worked very, very well and we're now going ahead and ordering those dies to come in. And so we're probably going to be ready to manufacture product in the next 60 to 90 days and then we will submit it for testing and start moving those products forward again. Speaker 200:16:28Fortunately for us, despite that delay, we've had so much to work on that that's only one project out of several. But we do think it's an important project and we are going to pick it back up as soon as we can manufacture it effectively. Speaker 400:16:42That was very helpful. Thanks for taking my questions and I'll get back in queue. Speaker 100:16:48Okay. Thank you. Operator00:16:58Our next question comes from Chris Vachowsky. Please proceed with your question. Speaker 500:17:06Good afternoon. Congratulations on very good results. Speaker 200:17:09Thank you, Chris. Speaker 500:17:12So during the LD Micro conference, you said that you wouldn't need any additional cash to reach profitability next year, given this quarter's cash yields. Are you do you still confirm this statement? Speaker 200:17:30Yes. So we are not going to need any cash to reach profitability. But I've also always said that if an opportunity presented itself or there was something accretive that we could purchase, that we would at that point do a financing tied directly to that. So as of right now, our cash loss was well below $500,000 and we still have $3,300,000 Fortunately, when you're ramping with some of these bigger companies that we now have, you're not dealing with payment terms like when you go into retail. So I think we're going to be okay right now. Speaker 200:18:02We're projecting profitability before we run out of cash with a pretty good cushion. But if there is something that we need to do and it means that that's going to allow us to scale and not have a hiccup in the way we scale, at that point we'll think about adding some cash. But as of right now, unless there's a really good reason that we're going to announce at the same time, we don't need any cash. Speaker 500:18:23Okay. This is very good to hear. So congratulations on great growth in Silverseal. And if I heard you correctly, Silverseal had very good sequential growth as well as annual. And was there any part of your business that shrunk sequentially because sequentially revenue did not grow that much? Speaker 200:18:49Sequentially revenues did not grow that much, but Silverseal grew. You always have a couple of products that you get rid of that didn't work out. So when you're launching a new product, especially when we test our products on Amazon, which is our model, those products will have a very high advertising rate compared to the profitability. So they're really not profitable as you start acquiring various customers. And then what we do is we watch the overall advertising drop if the product is popular because you get reorders, you get subscribed and saves and then you have to get to a certain threshold, which is probably around 25% to 30% tacos and our heroes are much lower than that. Speaker 200:19:28But then the product seem to be scaling. We every all the time, not every product we put out works, we're dropping products that don't meet that criteria. So yes, there's a few products that we drop, that's part of the weeding and calling process. But the real growth in Silverseal is no longer going to come from sequential growth on Amazon because that's a limited market. The next step for us is going to be retail and foreign markets and that's what's coming in the near future. Speaker 500:19:56Okay. And the retail, you said, is going to be sometime next year? Speaker 200:20:02Yes. I think it's reasonable to think midsummer around that time. There's just a process that retailers go through. All of our meetings have gone extremely well. There's a lot of interest on several products, not just SilverSeal, because we have probably 3 to 4 hero products now that we think would be viable at retail. Speaker 200:20:18And as I get a clearer picture, we'll give you updates on the next quarterly call as to exactly when we think we'll have products in the marketplace. Speaker 500:20:26Okay. And it seems that at least financially, it seems that you fit the profile of a company undergoing strong sequential growth, your accounts receivable are growing, you're investing more money in inventory. So any comments for Q4? Are we going to see sequential growth again? Speaker 200:20:48We really don't give guidance as to the quarters. I will tell you that you're going to continue to see very strong growth from us. But remember, we also have very large customers that tend to kick in periodically. So it doesn't look like a straight line up like a flat hill. It looks more like a staircase. Speaker 200:21:04So it is always possible that you have a flat quarter. We kind of had a flat quarter this quarter. But then as new things are announced and new customers come online, you'll see large jumps. And that's kind of the pattern I think you can kind of take as a general description going forward. Does that make sense? Speaker 500:21:20Yes, yes. Thanks. Okay, this is it for me. Good luck to us all. Speaker 200:21:24Thank you very Operator00:21:29much. We have reached the end of our question and answer session. This concludes today's teleconference. Thank you for your participation. You may disconnect your lines now.Read morePowered by